Science Explorer Back to mapMap
Discussion
Company · Toulouse · France

InvivoGen (France)

invivogen.comROR OpenAlex
Research works
17
◆ 1% vs 2018-21
Citations
494
29.3 per fractional work
Top-10% rate
11.7%
all institutions 10.0%
Open access
56%
world 40%
International
38%
world 18%
InvivoGen (France)

Not ranked overall: InvivoGen (France) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does InvivoGen (France) work in?

In all years, 57% of research at InvivoGen (France) is in Life Sciences, 34% in Health Sciences. Its largest fields are Medicine (26%), Immunology and Microbiology (25%), Biochemistry, Genetics and Molecular Biology (23%). It does 2.3× the world's share of Life Sciences.

Life Sciences: 10 fractional works · 57.2% of its workImmunology and Microbiology: 4 fractional works · 25.3% of its workImmunology: 4 fractional works · 22.3% of its workVirology: 0 fractional works · 2.2% of its workMicrobiology: 0 fractional works · 0.8% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 22.7% of its workMolecular Biology: 2 fractional works · 9.4% of its workBiotechnology: 1 fractional works · 7.4% of its workGenetics: 1 fractional works · 4.7% of its workCancer Research: 0 fractional works · 1.0% of its workSmaller subfields together: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 8.5% of its workEcology, Evolution, Behavior and Systematics: 1 fractional works · 5.9% of its workSoil Science: 0 fractional works · 2.0% of its workFood Science: 0 fractional works · 0.7% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.7% of its workPharmaceutical Science: 0 fractional works · 0.7% of its workHealth Sciences: 6 fractional works · 34.2% of its workMedicine: 4 fractional works · 26.3% of its workInfectious Diseases: 1 fractional works · 4.3% of its workEpidemiology: 1 fractional works · 4.2% of its workOncology: 1 fractional works · 3.9% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 3.6% of its workDermatology: 0 fractional works · 2.4% of its workNeurology: 0 fractional works · 2.0% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 1.5% of its workImmunology and Allergy: 0 fractional works · 1.1% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 1.0% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.8% of its workSurgery: 0 fractional works · 0.7% of its workPhysiology: 0 fractional works · 0.4% of its workGenetics: 0 fractional works · 0.4% of its workHealth Professions: 1 fractional works · 7.2% of its workEmergency Medical Services: 1 fractional works · 3.3% of its workPharmacy: 0 fractional works · 3.0% of its workOccupational Therapy: 0 fractional works · 1.0% of its workNursing: 0 fractional works · 0.7% of its workNutrition and Dietetics: 0 fractional works · 0.7% of its workPhysical Sciences: 1 fractional works · 8.0% of its workEnvironmental Science: 1 fractional works · 4.4% of its workEnvironmental Chemistry: 0 fractional works · 2.0% of its workWater Science and Technology: 0 fractional works · 2.0% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.1% of its workEngineering: 0 fractional works · 1.7% of its workBiomedical Engineering: 0 fractional works · 1.7% of its workChemistry: 0 fractional works · 1.4% of its workOrganic Chemistry: 0 fractional works · 1.4% of its workPhysics and Astronomy: 0 fractional works · 0.4% of its workStatistical and Nonlinear Physics: 0 fractional works · 0.4% of its workSocial Sciences: 0 fractional works · 0.7% of its workSocial Sciences: 0 fractional works · 0.7% of its workSociology and Political Science: 0 fractional works · 0.7% of its workALL ITS WORKInvivoGen(France)17fractional works, all years
Life Sciences57%Physical Sciences8%Health Sciences34%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Immunology and Microbiology425.3%
    2. Biochemistry, Genetics and Molecular Biology422.7%
    3. Agricultural and Biological Sciences18.5%
    4. Pharmacology, Toxicology and Pharmaceutics00.7%
    1. Medicine426.3%
    2. Health Professions17.2%
    3. Nursing00.7%
    1. Environmental Science14.4%
    2. Engineering01.7%
    3. Chemistry01.4%
    4. Physics and Astronomy00.4%
    1. Social Sciences00.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at InvivoGen (France)?

Ranked on the quality score, Éric Pérouzel, Thierry Lioux and Daniel Drocourt lead among researchers whose main affiliation is InvivoGen (France).

  1. 1 Éric Pérouzel France · #810,712 worldwide 1.7k citations · 37 works
  2. 2 Thierry Lioux France · #1,111,116 worldwide 891 citations · 25 works
  3. 3 Daniel Drocourt France · #1,874,518 worldwide 931 citations · 24 works
All ranked researchers at InvivoGen (France)

What are the most cited papers from InvivoGen (France)?

The most cited paper from InvivoGen (France) is "Dectin-1 Is Essential for Reverse Transcytosis of Glycosylated SIgA-Antigen Complexes by Intestinal M Cells" (Nicolas Rochereau, Daniel Drocourt, Éric Pérouzel et al., 2013), with 188 citations. Next come "Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells" (152) and "Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting" (149).

Most cited papers
#PaperReleasedCitations
1 Dectin-1 Is Essential for Reverse Transcytosis of Glycosylated SIgA-Antigen Complexes by Intestinal M Cells Nicolas Rochereau, Daniel Drocourt, Éric Pérouzel et al. · PLoS Biology Open access 17 Sep 2013 188
2 Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells Rémi Planès et al. · Molecular Cell Open access 16 May 2022 152
3 Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting Alice Gutjahr, Capucine Phelip, Anne-Line Coolen et al. · Vaccines Open access 12 Oct 2016 149
4 Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine–Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING) Thierry Lioux, Marc-Antoine Mauny, Alain Lamoureux et al. · Journal of Medicinal Chemistry Open access 26 Oct 2016 124
5 Rational design of adjuvants targeting the C-type lectin Mincle Alexiane C. Decout, Sandro Silva‐Gomes, Daniel Drocourt et al. · Proceedings of the National Academy of Sciences Open access 21 Feb 2017 115
All 55 most cited papers, with filters and sorting

Which research topics does InvivoGen (France) publish most on?

By volume in 2022-now: Cancer Research and Treatments, Radiopharmaceutical Chemistry and Applications, Neuroblastoma Research and Treatments and interferon and immune responses.

Cancer Research and Treatments: 0 fractional worksRadiopharmaceutical Chemistry and Applications: 0 fractional worksNeuroblastoma Research and Treatments: 0 fractional worksinterferon and immune responses: 0 fractional worksImmune Cell Function and Interaction: 0 fractional worksImmune Response and Infl…0Immune Response and Inflammation: 0 fractional worksImmune cells in cancer: 0 fractional worksHIV Research and Treatment: 0 fractional worksNanoplatforms for cancer theranostics: 0 fractional worksCytomegalovirus and herpesvirus research: 0 fractional works
BiotechnologyRadiology, Nuclear Medicine and ImagingNeurologyImmunology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Cancer Research and Treatments Biotechnology 0 works
  2. 2 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
  3. 3 Neuroblastoma Research and Treatments Neurology 0 works
  4. 4 interferon and immune responses Immunology 0 works
  5. 5 Immune Cell Function and Interaction Immunology 0 works
  6. 6 Immune Response and Inflammation Immunology 0 works
  7. 7 Immune cells in cancer Immunology 0 works
  8. 8 HIV Research and Treatment Virology 0 works
  9. 9 Nanoplatforms for cancer theranostics Biomedical Engineering 0 works
  10. 10 Cytomegalovirus and herpesvirus research Epidemiology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available55.8%not open44.2%

World: 40% of research is openly available.

with international co-authors37.5%domestic only62.5%

World: 18% is written across borders.

How has InvivoGen (France)'s research output changed?

Output in 2022-2025 was 1% higher than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is InvivoGen (France) as a percentage of every work published that year, 0.0000048% in 2022.

0.000050%0.00010%InvivoGen (France)0.000036% in 2023200020102020

Fractional works of InvivoGen (France) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Toulouse

All research institutions in Toulouse

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about InvivoGen (France). Posts are plain text and can be reported.